Company Performance Metrics
- Terry Evans: CCO
Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of
ototoxicity and impact on survival.
Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperatures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo.
Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.
